Document is current
Any future updates will be listed below
-
Authors
Theodoris, Christina V. https://orcid.org/0000-0003-1658-1447
Xiao, Ling
Chopra, Anant
Chaffin, Mark D. https://orcid.org/0000-0002-1234-5562
Al Sayed, Zeina R.
Hill, Matthew C.
Mantineo, Helene
Brydon, Elizabeth M. https://orcid.org/0000-0002-6140-8005
Zeng, Zexian
Liu, X. Shirley
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
- License Information
-
More Information
Article History
Received: 29 March 2022
Accepted: 27 April 2023
First Online: 31 May 2023
Competing interests
: X.S.L. conducted this work while on faculty at Dana-Farber Cancer Institute and is now a board member and CEO of GV20 Therapeutics. P.T.E. has received sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb and Pfizer. P.T.E. has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. A.C. is an employee of Bayer US LLC (a subsidiary of Bayer AG) and may own stock in Bayer AG. E.M.B. was a full-time employee of Bayer when this work was performed. The remaining authors declare no competing interests.
